Thomas J. Herzfeld Advisors’s CRISPR Therapeutics CRSP Stock Holding History

Thomas J. Herzfeld Advisors’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-625	Closed	-$28.4K	–	204
2023 Q3	$28.4K	Hold	625	–	–	0.01%	142
2023 Q2	$35.1K	Hold	625	–	–	0.01%	135
2023 Q1	$28.3K	Hold	625	–	–	0.01%	120
2022 Q4	$25.4K	Hold	625	–	–	0.01%	126
2022 Q3	$41K	Hold	625	–	–	0.02%	104
2022 Q2	$38K	Hold	625	–	–	0.02%	119
2022 Q1	$39K	Buy	625 +225	+56%	+$14.1K	0.01%	128
2021 Q4	$30K	Hold	400	–	–	0.01%	160
2021 Q3	$45K	Sell	400 -15	-4%	-$1.88K	0.02%	139
2021 Q2	$67K	Sell	415 -2	-0.5%	-$243	0.03%	131
2021 Q1	$51K	Buy	417 +400	+2,353%	+$60.4K	0.02%	146
2020 Q4	$3K	Hold	17	–	–	﹤0.01%	258
2020 Q3	$2K	Buy	+17	New	+$1.51K	﹤0.01%	235

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Thomas J. Herzfeld Advisors's CRSP Position: Q4 2023 in Review

Thomas J. Herzfeld Advisors sold out of CRISPR Therapeutics (CRSP) in Q4 2023, closing a stake of 625 shares — an estimated $28.4K sold.

Thomas J. Herzfeld Advisors first reported a position in CRSP in Q3 2020 and held it in 13 quarters. The position peaked at $67K in Q2 2021. 472 funds tracked by Wall St. Rank hold CRSP as of Q4 2023.

Thomas J. Herzfeld Advisors reported no remaining CRISPR Therapeutics position as of Q4 2023 after selling out during the quarter.
Thomas J. Herzfeld Advisors sold 625 CRISPR Therapeutics shares in Q4 2023, an estimated $28.4K.
Thomas J. Herzfeld Advisors first reported a position in CRISPR Therapeutics in Q3 2020 and held it in 13 quarters.
Thomas J. Herzfeld Advisors's CRISPR Therapeutics position peaked at $67K in Q2 2021.
472 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q4 2023.

Based on Thomas J. Herzfeld Advisors's 13F filing for Q4 2023, filed 14 Feb 2024.